Filament Health Corp (NEO:FH, OTCQB:FLHLF) told investors it has completed what it believes to be the first botanical psilocybin export to Perth in Western Australia with the delivery of its drug candidate PEX010.
The shipment was received by Reset Mind Sciences Ltd, a psychedelic-focused subsidiary of Little Green Pharma, a biotechnology company dedicated to developing natural quality medicines to help those living with chronic conditions.
Reset will use its drug product for research purposes, the company said in a statement.
"The successful export of PEX010 to Australia is a major achievement for our team and demonstrates our significant regulatory capabilities," commented Filament Health chief operating officer Lisa Ranken.
“To our knowledge, this is the first legal shipment of a botanical psilocybin drug candidate to arrive in Australia, and we are pleased to see a natural option being explored by Australian researchers.”
Filament Health noted that since July 1, 2023, authorised psychiatrists in Australia have been able to prescribe psilocybin for treatment-resistant depression.
Reset is progressing its good manufacturing practice (GMP) licence application to manufacture psilocybin products for human consumption from botanically sourced psilocybin while the industry awaits publication of the Australian Therapeutic Goods Administration's Therapeutic Goods Order governing psilocybin production in Australia.
"This shipment of naturally sourced psilocybin, the first of its kind to Australia, is not only a significant milestone for Reset but also for Australia's burgeoning psilocybin industry," said Reset's chief operating officer Dr Leon Warne.
Filament Health is a clinical-stage natural psychedelic drug development company.